双重TTK/PLK1抑制在TNBC中具有强大的抗癌活性,作为单一治疗和组合治疗
Elisa Zanini1, Nicole Forster-Gross1, Felix Bachmann1
1Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
Frontiers in oncology
|August 26, 2024
概括
一种新型的氨酸氨酸激酶 (TTK) 和波罗类激酶1 (PLK1) 的双重抑制剂,BAL0891,在临床前模型中显示出强大的抗癌活性,包括三阴性乳腺癌 (TNBC). 这种双重抑制策略为癌症治疗提供了一个有希望的新途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸氨酸激酶 (TTK) 和波罗类激酶1 (PLK1) 是参与螺旋组装检查点 (SAC) 的基本激酶.
- 单独准TTK或PLK1已经在癌症治疗中显示出临床潜力.
- 此前尚未探索TTK和PLK1的双抑制.
研究的目的:
- 为了描述第一类双TTK/PLK1抑制剂,BAL0891.1.
- 评估BAL0891.1的体外和体内抗癌活性.
- 评估TTK/PLK1双抑制作为一种新的癌症治疗策略的潜力.
主要方法:
- 使用生化和蛋白质组学试验的作用机制研究.
- 细胞检测包括细胞周期分析和SAC完整性评估.
- 在三阴性乳腺癌 (TNBC) 鼠标模型中的体外抗增殖试验和体内疗效研究,单独或与化疗结合.
主要成果:
- BAL0891表现出长期的TTK抑制和暂时的PLK1抑制,导致加速的SAC破坏和线粒体退出.
- 在各种固体瘤细胞系中观察到广泛的抗增殖活性.
- 在TNBC模型中,BAL0891显示出显著的瘤回归,并在TNBC患者衍生的异种移植中约40%显示出强烈的抗癌活性.
- 与帕克利塔克塞尔的联合治疗导致治愈,而与卡博普拉丁的协同作用则取决于时间表.
结论:
- 双TTK/PLK1抑制是一种新且有前途的癌症治疗方法,特别是TNBC.
- BAL0891表现出强大的抗癌活性和潜在的有利治疗指数.
- 组合策略可能会扩大对这种新型治疗方法有反应的患者群体.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


